Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 24:13:843927.
doi: 10.3389/fneur.2022.843927. eCollection 2022.

Ring Finger Protein 213 in Moyamoya Disease With Pulmonary Arterial Hypertension: A Mini-Review

Yuting Luo  1 , Zhixin Cao  1 , Shaoqing Wu  2 , Xunsha Sun  1
Affiliations
Review

Ring Finger Protein 213 in Moyamoya Disease With Pulmonary Arterial Hypertension: A Mini-Review

Yuting Luo et al. Front Neurol. .

Abstract

Moyamoya disease (MMD), most often diagnosed in children and adolescents, is a chronic cerebrovascular disease characterized by progressive stenosis at the terminal portion of the internal carotid artery and an abnormal vascular network at the base of the brain. Recently, many investigators show a great interest in MMD with pulmonary arterial hypertension (PAH). Ring finger protein 213 (RNF213) is a major susceptibility gene for MMD and also has strong correlations with PAH. Therefore, this review encapsulates current cases of MMD with PAH and discusses MMD with PAH in the aspects of epidemiology, pathology, possible pathogenesis, clinical manifestations, diagnosis, and treatment.

Keywords: Moyamoya disease; RNF213; idiopathic pulmonary arterial hypertension; peripheral pulmonary artery stenosis; pulmonary arterial hypertension.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the review was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Shang S, Zhou D, Ya J, Li S, Yang Q, Ding Y, et al. . Progress in Moyamoya disease. Neurosurg Rev. (2020) 43:371–82. 10.1007/s10143-018-0994-5 - DOI - PubMed
    1. Ahn IM, Park DH, Hann HJ, Kim KH, Kim HJ, Ahn HS. Incidence, prevalence, and survival of Moyamoya disease in Korea: a nationwide, population-based study. Stroke. (2014) 45:1090–5. 10.1161/STROKEAHA.113.004273 - DOI - PubMed
    1. Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (‘Moyamoya’ disease) Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg. (1997) 99:S238–40. 10.1016/S0303-8467(97)00082-6 - DOI - PubMed
    1. Tho-Calvi SC, Thompson D, Saunders D, Agrawal S, Basu A, Chitre M, et al. . Clinical features, course, and outcomes of a UK cohort of pediatric Moyamoya. Neurology. (2018) 90:e763–70. 10.1212/WNL.0000000000005026 - DOI - PubMed
    1. Zhang X, Xiao W, Zhang Q, Xia D, Gao P, Su J, et al. . Progression in Moyamoya Disease: Clinical Feature, Neuroimaging Evaluation and Treatment. Curr Neuropharmacol. (2021). - PMC - PubMed

LinkOut - more resources